| pubmed-article:15501458 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15501458 | lifeskim:mentions | umls-concept:C0027819 | lld:lifeskim |
| pubmed-article:15501458 | lifeskim:mentions | umls-concept:C1707919 | lld:lifeskim |
| pubmed-article:15501458 | lifeskim:mentions | umls-concept:C0003234 | lld:lifeskim |
| pubmed-article:15501458 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:15501458 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:15501458 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15501458 | pubmed:dateCreated | 2004-10-25 | lld:pubmed |
| pubmed-article:15501458 | pubmed:abstractText | Doxorubicin (Dox) is one of the most useful chemotherapeutic agents for patients with advanced neuroblastoma (NB). A series of Dox analogs with bulky substitutions at the C-4' at amino-sugar have been designed to impair interactions between the drug and P-glycoprotein (P-gp), a multidrug drug resistance (MDR) transporter. Two analogs, WP744 and WP769, were selected and their biological properties were compared with Dox and the daunorubicin-based bisintercalator WP631. These novel Dox analogs may have antitumor activity beyond MDR evasion. | lld:pubmed |
| pubmed-article:15501458 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15501458 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15501458 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15501458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15501458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15501458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15501458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15501458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15501458 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15501458 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15501458 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:15501458 | pubmed:issn | 0022-4804 | lld:pubmed |
| pubmed-article:15501458 | pubmed:author | pubmed-author:PriebeWaldema... | lld:pubmed |
| pubmed-article:15501458 | pubmed:author | pubmed-author:AzizkhanRicha... | lld:pubmed |
| pubmed-article:15501458 | pubmed:author | pubmed-author:IngeThomas... | lld:pubmed |
| pubmed-article:15501458 | pubmed:author | pubmed-author:WuJianqiangJ | lld:pubmed |
| pubmed-article:15501458 | pubmed:author | pubmed-author:HarrisNathani... | lld:pubmed |
| pubmed-article:15501458 | pubmed:copyrightInfo | Copyright 2004 Elsevier Inc. | lld:pubmed |
| pubmed-article:15501458 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15501458 | pubmed:volume | 121 | lld:pubmed |
| pubmed-article:15501458 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15501458 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15501458 | pubmed:pagination | 187-96 | lld:pubmed |
| pubmed-article:15501458 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:meshHeading | pubmed-meshheading:15501458... | lld:pubmed |
| pubmed-article:15501458 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15501458 | pubmed:articleTitle | WP744 is a novel anthracycline with enhanced activity against neuroblastoma. | lld:pubmed |
| pubmed-article:15501458 | pubmed:affiliation | Children's Hospital Research Foundation, Department of Pediatric Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. thomas.inge@cchmc.org | lld:pubmed |
| pubmed-article:15501458 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15501458 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
